

*AFT Pharmaceuticals Limited*

*PO Box 33-203, Takapuna*

*Auckland, New Zealand*

*Telephone +64-9-488 0232*

*Facsimile +64-9-488 0234*

*Freephone 0800 423 823*

*Freefax 0800 423 874*

*email [customer.service@aftp pharm.com](mailto:customer.service@aftp pharm.com)*

*[www.aftp pharm.com](http://www.aftp pharm.com)*

**22 December 2015**

### **AFT Pharmaceuticals lists on the NZX Main Board and ASX**

Shares in AFT Pharmaceuticals Limited ("AFT"), began trading on the NZX Main Board and ASX today following the successful IPO that raised \$35.6 million through the issue and sale of new and existing shares.

The shares in the growing multinational pharmaceutical business have been issued at \$2.80 a share giving the company a market capitalisation of \$271 million on listing.

CEO, Dr Hartley Atkinson says the offer has been well supported and the listing represents an excellent result.

"We welcome a number of institutional investors and members of public across New Zealand and Australia as shareholders, including a significant number of doctors, dentists and pharmacists."

"We can now focus on our goals such as selling our existing products like *Maxigesic* to new international markets, and advancing our pipeline products like the *SURF Nebuliser*. The additional capital will enhance our ability to make the most of those identified opportunities."

In connection with the successful IPO, AFT has also issued 100 shares (7,700 shares in total) to each employee (excluding executive directors) credited as fully paid up at an issue price of \$2.80 per share, in consideration for their services as employees for the period through to 20 December 2015.

On listing, 11.23% of the shares in the company are held by 735 Members of the Public whose names appear on the share register and who hold at least a Minimum Holding of shares

("Members of the Public" and "Minimum Holding" having the meanings given to them in the Listing Rules).

The Sole Lead Manager for the Offer was First NZ Capital.

**Issued for AFT Pharmaceuticals by Dart Public Affairs**

Contact Ryan Malone, (021) 205-5149, [ryan.malone@dartpublicaffairs.co.nz](mailto:ryan.malone@dartpublicaffairs.co.nz)

**About AFT Pharmaceuticals Limited**

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. To date, AFT has sold its products principally in its home markets of Australia and New Zealand. AFT has also recently begun selling products through its sales force and third party distributors in Southeast Asia, as well as certain key innovative products globally through licensees and distributors.

AFT is focussed on growing revenues and earnings through (i) continued growth of its existing business in Australia and New Zealand; (ii) growing new business in Southeast Asia; and (iii) continuing development and introduction of key innovative products to sell in its home markets and in global markets through licensees and distributors.

AFT was founded in 1997 by Dr. Hartley Atkinson (CEO) and Marree Atkinson (Executive Director and Chief of Staff). AFT has always stood for selling products that it genuinely believes will improve the health of its end consumers.